- Home
- AUTL vs ATXS Comparison
AUTL vs ATXS Comparison
Compare AUTL & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUTL
- ATXS
- Stock Information
- Founded
- AUTL 2014
- ATXS 2008
- Country
- AUTL United Kingdom
- ATXS United States
- Employees
- AUTL N/A
- ATXS N/A
- Industry
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- AUTL Health Care
- ATXS Health Care
- Exchange
- AUTL Nasdaq
- ATXS Nasdaq
- Market Cap
- AUTL 360.6M
- ATXS 401.2M
- IPO Year
- AUTL 2018
- ATXS 2015
- Fundamental
- Price
- AUTL $1.51
- ATXS $5.20
- Analyst Decision
- AUTL Strong Buy
- ATXS Strong Buy
- Analyst Count
- AUTL 5
- ATXS 5
- Target Price
- AUTL $9.32
- ATXS $26.60
- AVG Volume (30 Days)
- AUTL 2.0M
- ATXS 398.4K
- Earning Date
- AUTL 05-08-2025
- ATXS 05-08-2025
- Dividend Yield
- AUTL N/A
- ATXS N/A
- EPS Growth
- AUTL N/A
- ATXS N/A
- EPS
- AUTL N/A
- ATXS N/A
- Revenue
- AUTL $10,120,000.00
- ATXS N/A
- Revenue This Year
- AUTL $277.74
- ATXS N/A
- Revenue Next Year
- AUTL $221.89
- ATXS N/A
- P/E Ratio
- AUTL N/A
- ATXS N/A
- Revenue Growth
- AUTL 496.00
- ATXS N/A
- 52 Week Low
- AUTL $1.11
- ATXS $3.56
- 52 Week High
- AUTL $5.00
- ATXS $12.92
- Technical
- Relative Strength Index (RSI)
- AUTL 49.38
- ATXS 53.03
- Support Level
- AUTL $1.32
- ATXS $3.56
- Resistance Level
- AUTL $1.45
- ATXS $4.18
- Average True Range (ATR)
- AUTL 0.16
- ATXS 0.45
- MACD
- AUTL 0.04
- ATXS 0.12
- Stochastic Oscillator
- AUTL 65.85
- ATXS 91.64
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.